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Abstract
Background
Alzheimer's disease and related forms of dementia are becoming increasingly prevalent with the aging of many populations.
The diagnosis of Alzheimer's disease relies on tests to evaluate cognition and discriminate between individuals with
dementia and those without dementia. The Mini-Cog is a brief, cognitive screening test that is frequently used to evaluate
cognition in older adults in various settings.
Objectives
The primary objective of this review was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's
disease dementia and related dementias in a community setting.
Secondary objectives included investigations of the heterogeneity of test accuracy in the included studies and potential
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sources of heterogeneity. These potential sources of heterogeneity included the baseline prevalence of dementia in study
samples, thresholds used to determine positive test results, the type of dementia (Alzheimer's disease dementia or all
causes of dementia), and aspects of study design related to study quality. Overall, the goals of this review were to determine
if the Mini-Cog is a cognitive screening test that could be recommended to screen for cognitive impairment in community
settings.
Search methods
We searched MEDLINE (OvidSP), EMBASE (OvidSP), PsycINFO (Ovid SP), Science Citation Index (Web of Science),
BIOSIS previews (Web of Science), LILACS (BIREME), and the Cochrane Dementia Group's developing register of
diagnostic test accuracy studies to March 2013. We used citation tracking (using the database’s ‘related articles’ feature,
where available) as an additional search method and contacted authors of eligible studies for unpublished data.
Selection criteria
We included all cross-sectional studies that utilized the Mini-Cog as an index test for the diagnosis of dementia when
compared to a reference standard diagnosis of dementia using standardized dementia diagnostic criteria. For the current
review we only included studies that were conducted on samples from community settings, and excluded studies that were
conducted in primary care or secondary care settings. We considered studies to be conducted in a community setting where
participants were sampled from the general population.
Data collection and analysis
Information from studies meeting the inclusion criteria were extracted including information on the characteristics of
participants in the studies. The quality of the studies was assessed using the QUADAS-2 criteria and summarized using risk
of bias applicability and summary graphs. We extracted information on the diagnostic test accuracy of studies including the
sensitivity, specificity, and 95% confidence intervals of these measures and summarized the findings using forest plots.
Study specific sensitivities and specificities were also plotted in receiver operating curve space.
Main results
Three studies met the inclusion criteria, with a total of 1620 participants. The sensitivities of the Mini-Cog in the individual
studies were reported as 0.99, 0.76 and 0.99. The specificity of the Mini-Cog varied in the individual studies and was 0.93,
0.89 and 0.83. There was clinical and methodological heterogeneity between the studies which precluded a pooled meta-
analysis of the results. Methodological limitations were present in all the studies introducing potential sources of bias,
specifically with respect to the methods for participant selection.
Authors' conclusions
There are currently few studies assessing the diagnostic test accuracy of the Mini-Cog in community settings. The limited
number of studies and the methodological limitations that are present in the current studies make it difficult to provide
recommendations for or against the use of the Mini-Cog as a cognitive screening test in community settings. Additional well-
designed studies comparing the Mini-Cog to other brief cognitive screening tests are required in order to determine the
accuracy and utility of the Mini-Cog in community based settings.
Plain language summary
A brief cogntive screening test (Mini-Cog) for the assessment of possible dementia
With the aging of our populations there are increasing numbers of older adults with memory complaints and possible
dementia. Identifying older adults who have dementia is important in order to help with planning their care needs and starting
dementia specific treatments. In order to diagnose dementia, healthcare professionals or other service providers rely on tests
of memory and other areas of cognition in combination with additional investigations. Brief memory tests, such as the Mini-
Cog, may be useful as screening tests to help identify those individuals that might benefit from further evaluation in order to
determine if dementia is present. The Mini-Cog is a brief cognitive test that involves an assessment of an older person's
ability to recall three words and draw a clock. In this review, we searched medical literature databases to identify studies
which evaluated how well the Mini-Cog is able to distinguish between individuals who have dementia and those who do not
have dementia when compared to in-depth evaluation by dementia specialists. Our review focussed on those studies that
were conducted in community based settings. We identified three unique randomised controlled studies that evaluated the
Mini-Cog. In these studies the accuracy of the Mini-Cog varied and importantly there were some potential limitations within
the studies which may have led to an overestimation of the accuracy of the Mini-Cog. Based on the information that we
obtained from our review, we felt that further research into the accuracy of the Mini-Cog was required before it could be
recommended for routine use for identifying dementia in community settings.
Background 
Target condition being diagnosed
Alzheimer's disease and related forms of dementia are common among older adults with a prevalence of 8% in
individuals over the age of 65 years, increasing to a prevalence of approximately 43% in adults aged 85 years and
older (Thies 2012). Given the increasing number of older adults in most developing countries, the prevalence of
dementia is expected to increase considerably in the coming years. Currently, an estimated 35 million individuals are
diagnosed with dementia worldwide and this number is expected to increase to 150 million by 2050 (Prince 2013).
Alzheimer's disease and related forms of dementia are incurable and result in considerable direct and indirect costs,
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both in terms of formal health care and lost productivity from both the affected individual and their caregivers (Thies 2012
). Despite being incurable, there are several benefits to diagnosing Alzheimer's disease and related dementias early in
the disease course. Most individuals with dementia, and their caregivers, would prefer to know a diagnosis of
dementia, and earlier diagnosis of Alzheimer's disease allows these individuals to make decisions regarding future
planning while they retain the capacity to do so (Prorok 2013). A diagnosis of dementia is also necessary to access
certain services and support for individuals and their caregivers, and pharmacological treatments such as
cholinesterase inhibitors (Birks 2006; Rolinski 2012) or memantine (McShane 2006; Wilkinson 2011) may help slow the
progression of the disease.
The diagnosis of Alzheimer's disease is clinical and based on a history of decline in cognitive functioning, in
memory and with deficits in at least one other area of cognitive functioning (for example apraxia, agnosia or
executive dysfunction). There must be a decline from a previous level of functioning which results in significant
social or occupational impairment (American Psychiatric Association 2000; McKhann 2011). A definitive diagnosis
of Alzheimer's disease can only be achieved at autopsy, but a clinical diagnosis using standardized criteria is
associated with a sensitivity of 81% and a specificity of 70% when compared to autopsy-proven cases (Knopman 2001).
Approximately 50% to 80% of all individuals with dementia are ultimately classified as having Alzheimer's disease (Blennow
2006; Brunnström 2009; CSHA 1994). While patients with dementias share common characteristics, subtle
differences can help to provide a diagnosis in the absence of neuropathological examination. A smaller
proportion of dementias are associated with dementia with Lewy bodies (Brunnström 2009) or Parkinson's disease
dementia (Aarsland 2005). Dementia with a mixed etiology is present in 10% to 30% of cases (Brunnström 2009; Crystal
2000; Feldman 2003). Vascular dementias may occur more abruptly or present with a step-wise decline in
cognitive functions over time and account for approximately 15% to 20% of dementias (Brunnström 2009; CSHA 1994; 
Feldman 2003; Lobo 2000). Patients experiencing frontotemporal dementia account for a smaller proportion of
dementias (4% to 8%) and often present with problems in executive function and changes in behaviour, while
memory is relatively preserved (Brunnström 2009; Greicius 2002). Distinguishing between different types of dementias is
important as the management and prognosis of dementia can vary depending on the dementia subtype.
Index test(s)
The Mini-Cog is a brief cognitive test consisting of two components, a delayed three-word recall and the clock
drawing test (Borson 2000). The Mini-Cog was initially developed in a community setting to provide a relatively brief
cognitive screening test. Different scoring algorithms were tested to determine which combination had the optimal
balance of sensitivity and specificity (McCarten 2011; Scanlan 2001). The Mini-Cog takes approximately three to five
minutes to complete in routine practice (Borson 2000; Holsinger 2007; Scanlan 2001). The Mini-Cog has been
reported to have little potential for bias in terms of education or language (Borson 2000; Borson 2005).
Clinical Pathway 
Dementia develops over a trajectory of several years. There is a presumed period when people are asymptomatic
although disease pathology may be accumulating. Individuals or their relatives may first notice subtle impairments of
short-term memory. Gradually, more cognitive deficits become apparent with difficulty completing complex tasks such
as management of finances or medications. At this point the attribution of cognitive and memory symptoms to normal
aging may cause delays in the diagnosis and treatment of Alzheimer's disease. This underscores the need for
accurate, brief cognitive screening tests to help distinguish the cognitive changes associated with normal aging from
the changes that might indicate dementia. Most older adults with memory complaints will first present to their general
practitioner or other primary healthcare provider. Primary healthcare providers may then administer brief cognitive
screening tests and, depending on the results of the cognitive screening, an individual may then have additional
investigations or cognitive tests to determine if dementia is present. In some settings, a positive result on a brief
cognitive screening test may result in a referral to a dementia specialist such as a neurologist, geriatrician or geriatric
psychiatrist. Some countries have also recommended that brief cognitive screening tests be administered to all older
adults in order to help screen for undetected or asymptomatic cognitive impairment (Cordell 2013), although there is
controversy about the utility of population based screening.
Alternative test(s)
We are not including alternative tests in this review because there are currently no standard tests available for the diagnosis
of dementia. 
The Cochrane Dementia and Cognitive Improvement Group (CDCIG) is conducting a series of diagnostic test accuracy
reviews of biomarkers and scales (see list below). Although the CDCIG is conducting reviews on individual tests compared to
a reference standard, we plan to compare our results in an overview.
Positron emission tomography F-2-fluoro-2-deoxy-D-glucose (18F-FDG-PET)
Positron emission tomography Pittsburgh compound-C (11C-PIB-PET)
Structural magnetic resonance imaging (sMRI)
Neuropsychological tests (Mini Mental State Examination (MMSE); Montreal Cognitive Assessment (MoCA))
Informant interviews (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); AD8)
Apolipoprotein e4 (APOE e4)
Fluoropropyl-carbomethoxy-iodophenyl-tropane single-photon emission tomography (FP-CIT SPECT)
Rationale
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Cognitive diagnostic tests are required to assess cognition and assist in diagnosing conditions such as mild cognitive
impairment and dementia. Comprehensive neuropsychological evaluation conducted by psychologists or dementia
specialists such as general psychiatrists, geriatric psychiatrists, geriatricians or neurologists would be the most
accurate clinical procedure for assessing cognition and diagnosing dementia in older adults. However, these
specialized resources are scarce and expensive and as such are not practical for routine use in the evaluation of
cognitive complaints (Pimlott 2009; Yaffe 2008). While there are some cognitive tests that can be performed by
healthcare providers who are not dementia specialists, many of these tests are time consuming and may not be
practical to use routinely in primary care or community settings (Brodaty 2006; Harris 2009; Pimlott 2009). As such,
brief but relatively accurate cognitive screening tests are required for healthcare providers in community settings to
identify individuals who may require more in-depth evaluation of cognition. It has been recommended that brief
cognitive screening tests for community settings should be simple, take less than five minutes to administer, have a
misclassification rate similar to or better than the MMSE and have a negative value similar to or better than the
MMSE (Brodaty 2006).
Utilizing a standard diagnostic or screening tests also promotes effective communication between healthcare
providers. The sensitivity and specificity of such tests vary depending upon the setting in which they are utilized (Holsinger
2007). Some studies have found that the majority of older adults with dementia in primary care are undiagnosed (Boustani
2005; Sternberg 2000). In addition, many primary care providers have difficulty in accurately diagnosing dementia, and
mild dementia is particularly under-diagnosed (van den Dungen 2011). Early diagnosis and treatment of dementia
can have clinical and economic benefits for the patient, their community and the public healthcare system (Bennett 2003; 
Thies 2012). Accurate diagnosis of dementia is also important in order to initiate dementia therapeutics including both
non-pharmacological and pharmacological treatments such as cholinesterase inhibitors (Birks 2006; Rolinski 2012)
or memantine (McShane 2006). A brief and simple cognitive screening test that could be used in routine community
settings would allow healthcare professionals or lay people to initially screen older adults for the presence of
dementia. Individuals that screen positive for dementia on the Mini-Cog may then be further investigated for the
presence of dementia using additional cognitive tests or other investigations. Given that the Mini-Cog is brief, widely
available and easy to administer (Brodaty 2006), it may be well suited for use as a cognitive screening test in
community settings. Other cognitive screening tests that may also be suitable for use in the community or primary
care settings include the MMSE (Holsinger 2007), the General Practitioner Assessment of Cognition (Brodaty 2002)
or the Memory Impairment Screen (Buschke 1999). The current review examined the diagnostic accuracy of the Mini-Cog in
community settings. Separate diagnostic test accuracy reviews are being undertaken for primary and secondary care
settings.
Objectives 
To determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and related dementias in a
community setting.
Secondary objectives
To investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These
potential sources of heterogeneity include the baseline prevalence of dementia in study samples, thresholds used to
determine positive test results, the type of dementia (Alzheimer's disease dementia or all causes of dementia), and aspects
of study design related to study quality.
We will also identify gaps in the evidence where further research is required.
Methods 
Criteria for considering studies for this review
Types of studies 
We included all cross-sectional, population based studies with a well-defined population that utilized the Mini-Cog as an
index cognitive screening test compared to a reference standard. The included studies utilized a reference standard to
determine whether or not a dementia was present. The included studies also had to utilize the Mini-Cog as a screening test
and not for confirmation of diagnosis. While some studies utilized the test on patients with a previously known diagnosis of
Alzheimer's disease or a related dementia, when possible, studies administered the index and reference tests to individuals
where their diagnosis was not already known.
Participants
Study participants were sampled from a community setting and may or may not have been ultimately diagnosed with
Alzheimer's disease or a related dementia. Participants may have had cognitive complaints or dementia at baseline although
their cognitive status should not have been known to the individual administering the Mini-Cog or the reference standard.
Studies on participants with a developmental disability which prevented them from completing the Mini-Cog were excluded.
Studies including participants in either primary or secondary care settings have been excluded as these are the topics of
other reviews.
Index tests
Mini-Cog test
The Mini-Cog consists of a three-word recall task and the clock drawing test. The standard scoring system involves
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assigning a score of 0 to 3 points on the word recall task for the correct recall of 0, 1, 2 or 3 words, respectively. The
clock drawing test is scored as being either 'normal' or 'abnormal'. A positive test on the Mini-Cog (that is dementia) is
assigned if either the delayed recall score is 0 out of 3 or if the delayed recall score is either 1 or 2 and the clock
drawing test is abnormal. A score of 3 on the delayed recall or 1 to 2 on delayed recall with a normal clock drawing is
a negative test (that is no dementia) (Borson 2000).
Studies had to include the results of the Mini-Cog.
Target conditions
Target conditions included any stage of Alzheimer's disease or other types of dementia including vascular dementia,
dementia with Lewy bodies, Parkinson's disease dementia or frontotemporal dementia.
Reference standards
While a definitive diagnosis can only be made post-mortem at autopsy, there are clinical criteria for diagnosis of
most forms of dementia. All dementia diagnostic criteria require that an individual have impairment in multiple areas
of cognition that result in impairment in daily functioning and are not caused by either the effects of a substance or
a general medical condition. The standard clinical diagnostic criteria commonly used for Alzheimer's disease
dementia include the National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable or possible
dementia (McKhann 1984; McKhann 2011), the Diagnostic and Statistical Manual of Mental Disorders (DSM) (American
Psychiatric Association 2000) or the International Classification of Diseases (ICD 2010) criteria. Diagnostic criteria for
other types of dementia include the National Institute of Neurological Disorders and Stroke and Association
Internationale pour la Recherché et l'Enseignement en Neurosciences (NINCDS-AIREN) criteria for vascular
dementia (Roman 1993), and standard criteria for dementia with Lewy bodies (McKeith 2005) and frontotemporal
dementia (McKhann 2001). The evaluation for dementia should also include a number of laboratory investigations,
many of which are useful for excluding alternative diagnoses (Feldman 2008). Additional procedures to help confirm the
diagnosis include specific findings on neuroimaging (either computed tomography or magnetic resonance imaging).
These investigations are typically used to confirm the diagnosis, rather than rule out the possibility of dementia. While
these clinical criteria for dementia were considered the reference standard for the purposes of our review, the sensitivity
and specificity of these clinical reference standards may vary when compared to neuropathological criteria for dementia
(Nagy 1998).
Search methods for identification of studies 
Electronic searches 
We searched MEDLINE (OvidSP) (1950 to March 2013), EMBASE (OvidSP) (1974 to 04 March 2013), PsycINFO (OvidSP)
(1806 to March week 1 2013), Science Citation Index (Web of Science) (1945 to March 2013), BIOSIS Previews (Web of
Science) (1926 to March 2013), and the Cochrane Dementia and Cognitive Improvement Group's developing register of
diagnostic test accuracy studies. See Appendix 1 for details of the sources searched, the search strategies used and the
number of hits retrieved, and to view the 'generic' search that is run regularly for the Cochrane Dementia and Cognitive
Improvement Group's registry.
We made no attempt to restrict studies based on sampling frame or setting in the searches developed. This was to maximize
sensitivity and allow inclusion on the basis of population based sampling to be assessed at testing (see below, Selection of
studies). We did not use search filters (collections of terms aimed at reducing the number needed to screen) as an
overall limiter because those published have not proved sensitive enough (Beynon 2013; Whiting 2011a). We did not apply
any language restriction to the electronic searches; we used translation services as necessary.
A single researcher with extensive experience of systematic reviews performed the searches. Two independent authors
conducted the screening of abstracts and titles.
Searching other resources 
We searched the reference lists of all relevant studies for additional relevant studies as this has been found to be
a useful method to minimize missing potentially relevant studies in complex reviews (Greenhalgh 2005; Horsley 2011). We
also used these studies to search the electronic databases to identify additional studies through the use of the related article
feature. We asked research groups authoring studies used in the analysis for unpublished data.
Data collection and analysis 
Selection of studies 
To be included, studies had to:
make use of the Mini-Cog as a cognitive diagnostic tool;1.
include patients from a community setting who may or may not have dementia or cognitive complaints; and2.
clearly explain how a diagnosis of dementia was either confirmed according to a reference standard such as the DSM IV-3.
TR or NINCDS-ADRDA at the same time or within the same four-week time period that the Mini-Cog was administered.
Formal neuropsychological evaluation was not required for a diagnosis of dementia.
We first selected articles based on abstract and title. Two independent authors located selected articles and assessed them
for inclusion. We settled disagreements by involving a third author.
DTA14 Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting
5 / 28
Data extraction and management
Two study authors extracted the following data from all included studies.
Author, journal and year of publication.
Scoring algorithm used for the Mini-Cog including cut-points used to define a positive screen. Method of Mini-Cog
administration, including who administered and interpreted the test, and their training and whether or not the raters of the
Mini-Cog and reference standard were blinded to the results of the other test.
Reference criteria and method used to confirm diagnosis of Alzheimer's disease or a related dementia.
Baseline demographic characteristics of the study population including age, gender, ethnicity, severity of presenting
symptoms, comorbidity, educational achievement, language, baseline prevalence of dementia, country, APOE status,
methods of participant recruitment and sampling procedures.
Length of time between administration of index test (Mini-Cog) and reference standard.
The sensitivity and specificity, positive and negative likelihood ratios of the index test in defining dementia.
Version of translation (if applicable).
Prevalence of dementia in the study population.
Assessment of methodological quality
We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria to assess data quality (Whiting
2011b). The QUADAS-2 criteria contain assessment domains for patient selection, index test, reference test, and flow and
timing. Each domain has suggested signalling questions to assist with the 'risk of bias' assessment for each domain. The
potential risk of bias associated with each domain is rated as being at high, low, or uncertain risk of bias. In addition, we
determined an assessment of the applicability of the study to the review study question for each domain using the guide
provided in the QUADAS-2. We utilized a standardized 'risk of bias' template to extract data on the risk of bias for each study
using the form provided by the UK Support Unit for Cochrane Systematic Reviews of Diagnostic Test Accuracy. See
Appendix 2 for details. We summarized quality assessment results using the methodological quality summary table
and methodological summary graph in RevMan 5.3 (RevMan 2012).
Statistical analysis and data synthesis
We performed statistical analysis as per the Cochrane guidelines for diagnostic test accuracy reviews (Macaskill 2010).
Study specific two-by-two tables were constructed using information extracted from the included studies. We planned to
construct separate two-by-two tables for Mini-Cog results for both Alzheimer's disease dementia and all-cause dementia.
We used data from two-by-two tables to calculate the study specific sensitivity, specificity, and positive and negative
likelihood ratios as well as measures of statistical uncertainty (for example 95% confidence intervals). We obtained
rates of false positives, true positives, false negatives, and true negatives from RevMan. We presented data from
each study graphically by plotting sensitivities and specificities on a coupled forest plot. The study specific
sensitivities and specificities were also plotted in the receiver operating curve (ROC) space. We planned to use the
bivariate random-effects model approach for meta-analysis of the sensitivity and specificity (Reitsma 2005). If multiple
thresholds were reported for the Mini-Cog we planned to use the hierarchical summary ROC (HSROC) method of
Rutter and Gastconis for meta-analysis (Rutter 2001). While meta-analysis was planned for this review, there were a limited
number of studies all of which had methodological limitations and as such meta-analysis was not undertaken with the final
results.
Investigations of heterogeneity
The potential sources of heterogeneity that we planned to examine included baseline prevalence of cognitive impairment in
the target population, the cut-points used to determine a positive test result, the type of dementia (Alzheimer's disease
dementia or all-cause dementia) and aspects related to study quality. To investigate the effects of the sources of
heterogeneity, we performed a descriptive analysis by visual examination of the forest plot of sensitivity and specificity and
the ROC plot. As meta-analysis was not undertaken in this review we were unable to perform any statistical analyses of
heterogeneity.
Sensitivity analyses
We planned to perform a sensitivity analysis in order to investigate the influence of study quality on the overall diagnostic
accuracy of the Mini-Cog test by omitting studies that were at high risk of bias on any of the QUADAS-2 domains. We also
planned to determine the impact of individual studies on summary outcome measures. However, due to the small number of
studies we were not able to conduct a meta-analysis and these sensitivity analyses were not undertaken.
Assessment of reporting bias
We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and
the interpretation of existing analytical tools such as funnel plots (Deeks 2005; van Ernst 2014).
Results 
Results of the search
The results of the literature search are outlined below in Figure 1. A review of the electronic databases yielded 108 articles in
September 2012 and 106 in January 2013, and an additional 2 were identified through handsearches. After de-duplication
this left 110 articles. All 110 were independently assessed by two authors and there were no disagreements about either the
number of studies eligible for inclusion or data results.
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After initial evaluation, 38 studies were assessed for eligibility. Of these, 34 were excluded. Reasons for exclusion included
the lack of a reference standard (N = 15), no use of the Mini-Cog (N = 5), duplicate publication (N = 5), inappropriate setting
(N = 6) and insufficient available data (N = 3).
The search identified three independent studies from four different study reports. A summary of the characteristics of the
included studies are provided in Table 1. Notably, all of the studies were published by the same author group. Borson 2000
was the first study to use the Mini-Cog, sampling a multilingual population of older adults identified through community social
services agencies. Of the 249 participants, 124 were non-English speaking. The study aimed to compare the newly-
developed Mini-Cog with the MMSE and Cognitive Abilities Screening Instrument (CASI). The diagnosis of dementia was for
all-cause dementia although the majority of participants in this study had Alzheimer's disease.
Borson 2003 included the largest sample size, utilizing a random sample of 1119 older adults enrolled in the Monogahela
Valley Independent Elders Survey (MoVIES). The study was a post hoc analysis, using combined data from standard
neuropsychological testing to create the Mini-Cog. The study found that the Mini-Cog, when compared to the MMSE at a cut-
point of 25, had similar sensitivity and specificity for differentiating between 'possibly impaired' and 'probably normal'. The
diagnosis of dementia in this study was specifically for Alzheimer's disease dementia.
Two reports (Borson 2005/2006) used the same study sample. The 2005 report again compared the Mini-Cog and MMSE,
determining that the tools were similar in detecting clinically significant cognitive impairment. The 2006 report re-examined
the data in an attempt to compare the accuracy of the Mini-Cog when compared to spontaneous detection by primary care
physicians. The diagnosis of dementia in this study was Alzheimer's disease dementia.
Further details concerning the design, setting, population, target condition and reference standard of the four included
studies can be found in the Characteristics of included studies.
Methodological quality of included studies
The results of the QUADAS-2 assessment for each of the three included studies are presented in Figure 2. All studies were
judged as being at high risk of bias in the patient selection domain. For Borson 2000 and Borson 2005/2006 it was unclear
whether or not a consecutive, random sampling of patients was employed, and all studies failed to avoid inappropriate
exclusions for a variety of reasons (incomplete health records, visual or motor impairment, failure to meet minimum
education requirements). In addition, the reference standard assessment used in Borson 2000 was administered and
interpreted with knowledge of the Mini-Cog results, introducing a high risk of bias.
Two of the studies excluded individuals with questionable dementia from the analysis (Borson 2000; Borson 2003).
Therefore the analysis of the accuracy of the Mini-Cog in these studies was limited to individuals with normal cognition and
those with certain diagnoses of dementia. It was likely that this may introduce a spectrum bias to the results as the Mini-Cog
would only be comparing individuals who had no dementia to those with more severe cognitive impairment.
A few additional features common to all the included studies may have introduced other potential sources of bias. First, all
studies were published by the same author group. Second, all studies used a version of the Mini-Cog that was derived from
components of larger neuropsychological tests (that is using the three-word recall from the MMSE). The performance of the
Mini-Cog when the component tests were administered by themselves as compared to when the results of the Mini-Cog were
derived from the results of more comprehensive testing may also have affected the accuracy of the Mini-Cog.
Findings
There were four study reports on three unique study populations that were selected for the final review (Borson 2000; 
Borson 2003. Borson 2005/2006). The characteristics of these studies are summarized in the Characteristics of included
studies section of this review. Additional features of these studies are also summarized in Summary of findings table 1.
Two of the publications reported on the same study sample (Borson 2005/2006) and information from both
publications were used to complete the quality assessment for this study. All of the studies were completed by the
same research group. Two studies recruited participants from community settings, who were then assessed at a
memory clinic (Borson 2000; Borson 2005/2006) and the third study evaluated a random sample of community
dwelling individuals from a defined geographic area (Borson 2003). Two of the studies also excluded individuals with
mild cognitive impairment or possible dementia, only including individuals who were cognitively normal or had
dementia in the final analysis (Borson 2000; Borson 2003). The baseline prevalence of dementia in the overall study
samples varied from 6.8% (Borson 2003) to 51.8% (Borson 2000). All studies utilized the original scoring system
proposed by Borson et al (Borson 2000).
Meta-analysis of the diagnostic test accuracy of the Mini-Cog was planned, although due to the small number of studies and
methodological limitations of included studies we did not perform a meta-analysis. The extracted data, including sensitivity,
specificity and forest plots for the Mini-Cog in each study, are summarized in Summary of findings table 1 and in the forest
plot presented in Figure 3. The sensitivities of the Mini-Cog in the individual studies were reported as 0.99 (Borson 2000
), 0.76 (Borson 2003) and 0.99 (Borson 2005/2006). The specificity of the Mini-Cog varied in the individual studies
and was 0.93 (Borson 2000), 0.89 (Borson 2003) and 0.83 (Borson 2005/2006). The values for the positive and negative
predictive values and positive and negative liklihood ratios for the individual studies are summarized in the Summary of
findings table 1 and in Figure 3.
The small number of studies and overall poor quality of the included studies precluded the use of meta-analysis to
arrive at pooled estimates for the diagnostic test accuracy. The study specific sensitivity and specificity were plotted in
a forest plot (Figure 3) and the summary test characteristics of the individual studies were plotted in a graph (Figure 4).
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Discussion 
Summary of main results
The Mini-Cog is a commonly utilized brief cognitive screening test that has been recommended as a potential cognitive
screening test for community settings. Our review found that there are only three studies that evaluated the Mini-Cog in
community settings. These three studies were all conducted by the original developers of the Mini-Cog. The sensitivity and
specificity of the Mini-Cog in these studies were relatively high in two of the studies, which may be influenced by significant
methodological limitations that may have led to overestimation of the accuracy of the Mini-Cog due to the exclusion of
individuals with mild cognitive impairment or possible dementia. The results of this review suggest that the Mini-Cog may be
useful in distinguishing between individuals with moderate to severe cognitive impairment when compared to individuals with
normal cognition. Overall, additional well-designed studies with large sample sizes are required to better evaluate the
accuracy of the Mini-Cog in order to determine whether it can be recommended as a screening test for dementia.
Strengths and weaknesses of the review
There are several strengths to this review. We used a standardized search strategy to identify potential articles including
unpublished studies, which would reduce the risk of publication bias. These search methods included a single-concept
search across multiple sources along with a search of the Cochrane Collaboration diagnostic test accuracy registry. This
sensitive search approach may have identified studies that would have potentially been overlooked using less rigorous
search methods. Our review also provided a detailed assessment of the quality using the QUADAS-2, which provides
important information about potential sources of bias in the included studies and provides context for the interpretation of the
reported results.
Some weaknesses of this review are related to the small number of studies that have been conducted. Also, the
methodological limitations of the included studies limits the conclusions that can be drawn from the current studies
that have evaluated the Mini-Cog in community settings. In particular, two of the three studies that were included in
this review (Borson 2000; Borson 2003) excluded individuals with questionable or uncertain dementia from the analysis,
which may have led to overestimation of the accuracy of the Mini-Cog. The Mini-Cog was only evaluated in a single country
and its accuracy for detecting dementia in community settings outside of the United States is not known. Also, all of the
studies included in this review derived the Mini-Cog scores from components of larger neuropsychological tests. It is likely
that the Mini-Cog will frequently be utilized differently in routine clinical settings and the accuracy of the Mini-Cog when
performed as a single test may differ when compared to when it is derived from a larger test. In particular, the amount of time
that passes between the administration of the three words and the recall of these three words may differ with these different
methods of administration, which may affect the accuracy of the Mini-Cog for detecting dementia.
Applicability of findings to the review question
Our review question was to determined the accuracy of the Mini-Cog in the diagnosis of dementia in a community
setting. Of the three studies identified in this review, only one (Borson 2003) study was conducted using methods that would
closely replicate how the Mini-Cog would typically be used in community based settings. Therefore, the results of only a
single study are available on the use of the Mini-Cog in a manner that most closely matched the research question of this
review.
Authors' conclusions 
Implications for practice 
At the present time there is insufficient evidence to recommend the use of the Mini-Cog as a screening test for
dementia in community settings. Individuals in community settings who are being screened for cognitive impairment
are likely to have a wide range of cognitive abilities, ranging from normal cognitive aging to advanced dementia. The
information currently available on the diagnostic test accuracy of the Mini-Cog in community settings is limited by the
poor quality of the studies. In particular, two of the three studies which evaluated the Mini-Cog excluded individuals
with mild cognitive impairment or possible dementia from the study populations, which likely leads to overestimation
of the accuracy of the Mini-Cog for detecting milder forms of cognitive impairment or dementia. Therefore, the
accuracy of the Mini-Cog for diagnosing mild dementia is unknown at this time, although it would be anticipated that
the use of the Mini-Cog for detecting mild dementia would be less accurate in diagnosing early dementia when
compared to more advanced dementia. Two of the studies included in our review included study populations with
more advanced dementia. Although there is limited information to support the Mini-Cog as an accurate brief screening
test, the Mini-Cog has been recommended as a potential initial screening test for primary care settings (Cordell 2013) and
a systematic review concluded that the Mini-Cog had acceptable test performance for screening of cognitive impairment (
Lin 2013).
Another consideration with the use of the Mini-Cog in clinical practice relates to the study population in which it is used.
The prevalence of dementia among adults aged 65 years and older in community settings is typically reported to be
between 5% and 8% (CSHA 1994; Matthews 2013), in contrast the prevalence of dementia in two of the studies which
evaluated the Mini-Cog were 44.4% and 51.8%. The high prevalence of dementia in these studies also likely affected the
accuracy of the Mini-Cog, overestimating the positive predictive value of the Mini-Cog in these populations when compared
to a more typical community sample with a lower prevalence of dementia.
In community settings where the prevalence of dementia is low, screening for cognitive impairment has been
recommended by some health administrators and the Mini-Cog has been recommended as one potential initial
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cognitive screening tool among others such as the Memory Impairment Screen and General Practitioner Assessment
of Cognition (Cordell 2013). In the current review direct comparisons of the diagnostic test accuracy of the Mini-Cog
when compared to other cognitive tests were not undertaken. Separate reviews of the diagnostic test accuracy of
some of these screening tests are being completed (Creavin 2014; Harrison 2014; Hendry 2014). Therefore, the relative
accuracy of the Mini-Cog when compared to longer cognitive screening tests are not known and clinicians will need to
consider the known strengths and limitations of the Mini-Cog when compared to other, longer cognitive tests.
There are, however, some potential reasons why clinicians may consider using the Mini-Cog despite these limitations. The
Mini-Cog is a very brief screen and as such it can be utilized in settings where there may be limited time or resources
available to clinicians to complete a brief cognitive screening test which may guide further investigations. The Mini-Cog is
also easy to administer from memory and doesn't require any special forms or access to a computer to complete, which is
another reason that it may have some utility for clinicians in some clinical situations.
Implications for research 
There are several opportunities for additional research on the diagnostic test accuracy of the Mini-Cog in community
settings. A large, well-designed community based study evaluating the diagnostic test accuracy of the Mini-Cog
would provide important additional information about the the accuracy of the Mini-Cog. It would be important in future
studies to include a more representative sample of community dwelling older adults who have a broader range of
underlying cognitive abilities including individuals with normal cognition, mild cognitive impairment, early dementia
and more advanced dementia to better understand the accuracy of the Mini-Cog in these specific populations. We
did not compare the Mini-Cog against other brief cognitive screening tests such as the MMSE that are subjects of
separate Cochrane reviews (Creavin 2014; Harrison 2014; Hendry 2014). The potential advantage of the Mini-Cog is that it is
very brief, even when compared to other cognitive screening tests. Whether the Mini-Cog is as accurate when compared to
other brief screening tests was not evaluated in the current review but may be important to study in future reviews.
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Differences between protocol and review 
Published notes 
Characteristics of studies
Characteristics of included studies 
Borson 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Patients were identified through community
social service agencies and evaluated at the
University of Washington's Alzheimer's Disease
Research Center. Excluded individuals with
Clinical Dementia Rating = 0.5
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Patients were selected regardless of
language spoken, education, race.
Patients were excluded when they had a
history of severe brain injury, CNS
infection, active alcohol or drug abuse
history, poorly controlled diabetes or
kidney, heart, respiratory failure
Participant mean age (SD), dementia:
77.9 (9.1), no dementia: 69.0 (9.0)
Gender: 173 women, 76 men
Education: varied
Dementia: 129, no dementia: 120
Mean MMSE Scores (SD), dementia:
14.1 (6.7), no dementia: 27.5 (2.4)
Are there concerns that the included patients and setting do not match the review
question? Unclear
Index Test
Index tests
Mini-Cog using original scoring and Mini-Cog score was derived from the Cognitive Abilities Screening
Instrument
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Clinical diagnosis of dementia based on
criteria of DSM-IV, CERAD and
NINCDS-ADRDA
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? No
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing All patients were reported
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Borson 2003
Patient Selection
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A. Risk of Bias
Patient Sampling
Age stratified, random sample for 65 year old and
older from population of 17,000 adults across 23
communities in Pennsylvannia. Individuals with
questionable dementia (CDR = 0.5) were excluded
from the analysis
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Patients were English speakers, 65 year
old and older with > 6 years of formal
education and living in the community
Participant age: mean age (SD) 73.1 (6)
Gender: 611 women, 508 men
Education: median 12 years, minimum 6
years of formal education
Dementia: 76, no dementia: 1043
Mean MMSE Scores (SD): dementia 21.3
(5.8), no dementia 27.8 (1.9)
Are there concerns that the included patients and setting do not match the review
question? Low concern
Index Test
Index tests Mini-Cog scored according to Borson 2000
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Clinical diagnosis of dementia, as per the
criteria of DSM-IV-TR and NINDS-
ADRDA
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing Complete data for all patients
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
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Notes  
Borson 2005/2006
Patient Selection
A. Risk of Bias
Patient Sampling
Non-random sampling of patients referred to
University of Washington Alzheimer
Disease Research Center Satellite by
community service agencies and other
outreach methods
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Heterogeneous community sample that was over-
represented with ethnic minority elderly. Patients
with motor or sensory impairment precluding
administration of cognitive screens were excluded.
Patients with fragmentary outpatient records were
excluded
Participant age: unclear
Gender: unclear
Education: unclear
Severity of cognitive impairment, Alzheimer's
disease dementia: 112, no dementia:140
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Mini-Cog derived from a larger neuropsychological test battery, the Cognitive Abilities Screening
Instruments
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Clinical diagnosis of dementia based on
the criteria of DSM-IV, NINCDS-ADRDA.
Patients were evaluated by consensus
process that excluded cognitive testing
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing Complete data on all patients
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Footnotes
Characteristics of excluded studies 
Costa 2012
Reason for exclusion Study did not have gold standard evaluation using standardized diagnostic criteria.
Unclear whether participants were without dementia or cognitive complaints at
baseline
 
Lorentz 2003
Reason for exclusion Insufficient information.
 
Scanlan 2004
Reason for exclusion Study did not have gold standard evaluation using standardized diagnostic criteria
 
Scanlan 2007
Reason for exclusion Study did not have gold standard evaluation using standardized diagnostic criteria
 
Tappen 2010
Reason for exclusion Study did not have gold standard evaluation using standardized diagnostic criteria.
Unclear if all participants were without dementia or cognitive complaints at baseline
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
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Title: Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting
Population Community-dwelling older adults
Setting
Community setting was intended to represent a population based sample of older adults in which the Mini-Cog
may be used as a screening tests. Studies that included populations where participants were identified from
community settings but then evaluated using the Mini-Cog and reference standard were included in the review
Index test Mini-Cog either administered as a single test or Mini-Cog scores for the clock drawing test and three-worddelayed recall were derived from larger tests
Reference
Standard Clinical diagnosis of dementia using any recognized classification system
Studies  Cross-sectional studies, case control studies were excluded
Study Accuracy(95% CI)
Number of
participants
Dementia
prevalence Implications
Borson
2000
Sensitivity:
0.99 (0.96 to
1.00)
Specificity:
0.93 (0.87 to
0.97)
Positive LR:
14.88
Negative LR:
0.0083
249 51.8%
Excluded individuals with questionable dementia (CDR = 0.5) from
study population, accuracy of Mini-Cog in diagnosing mild dementia
not determined which may have overestimated the accuracy of the
Mini-Cog. The prevalence of dementia is higher than would be
anticipiated from most community based studies
Borson
2003
Sensitivity:
0.76 (0.65 to
0.85)
Specificity:
0.89 (0.87 to
0.91)
Positive LR:
6.92
Negative LR:
0.07
1119 6.8%
Excluded individuals with questionable dementia (CDR = 0.5) from
analysis which may have resulted in an overestimation of the
accuracy of the Mini-Cog
Borson
2005/2006
Sensitivity:
0.99 (0.95 to
1.00)
Specificity:
0.83 (0.76 to
0.89)
Positive LR:
5.78
Negative LR:
0.01
252 44.4%
Individuals referred from community agencies to Alzheimer's centre.
The prevalence of dementia is higher that would be expected from
most community based studies, which may have affected the test
accuracy of the Mini-Cog
Footnotes
Additional tables 
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Study ID Country Participants(N) Setting
Mini-Cog
scoring
Dementia
diagnosis
Dementia
prevalence Notes
Borson 2000 Seattle, US 249
Community sample
assessed at memory
clinic
Standard
scoring
DSM-IV,
NINCDS-
ADRDA
51.8%
Excluded
participants with
MCI
Borson 2003 Pennsylvania,US 1119
Random sample of
persons in geographic
region
Standard
scoring
DSM-III R,
NINCDS-
ADRDA
6.8%
Excluded
participants with
MCI
Borson
2005/2006 Seattle, US 252
Community sample
referred for cognitive
screening
Standard
scoring
DSM-IV,
NINCDS-
ADRDA
44.4%  
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Caption
Study flow diagram.
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Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies.
Figure 3 (Analysis 1) 
Caption
Forest plot of 1 Mini-Cog (Community).
Figure 4 (Analysis 1) 
Caption
Plot of study sensitivity and specificity in receiver operating curve space.
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Appendices 
1 Sources searched and search strategies
 
Source
Search strategy Hits
retrieved
ALOIS DTA (CDCIG Specialised Register) (see below for detailed
explaination of what is contained within the ALOIS register)
 
Mini-cog
Sept 2012:
19
Jan 2013: 0
1. MEDLINE In-Process and other non-indexed citations and
MEDLINE 1950 to present (January 2013) (Ovid SP)
 
1. "mini-Cog".ti,ab.
2. minicog.ti,ab.
3. (MCE and (cognit* OR dement* OR
screen* OR Alzheimer*)).ti,ab.
3. or/1-3
Sept 2012:
91
Jan 2013:
12
2. EMBASE
1974-2013 January 02 (OvidSP)
 
1. "mini-cog*".mp.
2. minicog*.mp.
3. 1 or 2
Sept 2012:
96
Jan 2013:
37
3. PsycINFO
1806 to January week 1 2013 (OvidSP)
 
1. minicog*.mp.
2. "mini-cog*".mp.
3. 1 or 2
Sept 2012:
69
Jan 2013:
28
4. Biosis previews 1926 to present (January 2013) (ISI Web of
Knowledge)
 
Topic=("mini-cog*" OR "minicog*")
Timespan=All Years. Databases=BIOSIS
Previews.
Lemmatization=On
Sept 2012:
33
Jan 2013: 7
5. Web of Science and conference proceedings (1945 to January
2013)
 
Topic=("mini-cog*" OR "minicog*")
Timespan=All Years. Databases=BIOSIS
Previews.
Lemmatization=On
Sept 2012:
93
Jan 2013:
20
6. LILACS (BIREME) (January 2013) "mini-cog" OR minicog [Words] Sept 2012:
2
Jan 2013: 2
TOTAL before de-duplication Sept 2012:
403
Jan 2013:
106
TOTAL after de-dupe and first-assess Sept 2012:
108
Jan 2013:
41
In addition to the above single concept search based on the Index test, the Cochrane Dementia and Cognitive Improvement
Group run a more complex, multi-concept search each month primarily for the identification of diagnostic test accuracy
studies of neuropsychological tests. Where possible the full texts of the studies identified are obtained. This approach is
expected to help identify those papers where the index test of interest (in this case Mini-cog) is used and the paper contains
usable data but where Mini-cog was not alluded to in the report's citation.
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The MEDLINE strategy used is below. Similar strategies are also run in EMBASE and PsycINFO.
The MEDLINE generic search run for the CDCIG DTA register:
1. "word recall".ti,ab.
2. ("7-minute screen" OR “seven-minute screen”).ti,ab.
3. ("6 item cognitive impairment test" OR “six-item cognitive impairment test”).ti,ab.
4. "6 CIT".ti,ab.
5. "AB cognitive screen".ti,ab.
6. "abbreviated mental test".ti,ab.
7. "ADAS-cog".ti,ab.
8. AD8.ti,ab.
9. "inform* interview".ti,ab.
10. "animal fluency test".ti,ab.
11. "brief alzheimer* screen".ti,ab.
12. "brief cognitive scale".ti,ab.
13. "clinical dementia rating scale".ti,ab.
14. "clinical dementia test".ti,ab.
15. "community screening interview for dementia".ti,ab.
16. "cognitive abilities screening instrument".ti,ab.
17. "cognitive assessment screening test".ti,ab.
18. "cognitive capacity screening examination".ti,ab.
19. "clock drawing test".ti,ab.
20. "deterioration cognitive observee".ti,ab.
21. ("Dem Tect" OR DemTect).ti,ab.
22. "object memory evaluation".ti,ab.
23. "IQCODE".ti,ab.
24. "mattis dementia rating scale".ti,ab.
25. "memory impairment screen".ti,ab.
26. "minnesota cognitive acuity screen".ti,ab.
27. "mini-cog".ti,ab.
28. "mini-mental state exam*".ti,ab.
29. "mmse".ti,ab.
30. "modified mini-mental state exam".ti,ab.
31. "3MS".ti,ab.
32. “neurobehavio?ral cognitive status exam*”.ti,ab.
33. "cognistat".ti,ab.
34. "quick cognitive screening test".ti,ab.
35. "QCST".ti,ab.
36. "rapid dementia screening test".ti,ab.
37. "RDST".ti,ab.
38. "repeatable battery for the assessment of neuropsychological status".ti,ab.
39. "RBANS".ti,ab.
40. "rowland universal dementia assessment scale".ti,ab.
41. "rudas".ti,ab.
42. "self-administered gerocognitive exam*".ti,ab.
43. ("self-administered" and "SAGE").ti,ab.
44. "self-administered computerized screening test for dementia".ti,ab.
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45. "short and sweet screening instrument".ti,ab.
46. "sassi".ti,ab.
47. "short cognitive performance test".ti,ab.
48. "syndrome kurztest".ti,ab.
49. ("six item screener" OR “6-item screener”).ti,ab.
50. "short memory questionnaire".ti,ab.
51. ("short memory questionnaire" and "SMQ").ti,ab.
52. "short orientation memory concentration test".ti,ab.
53. "s-omc".ti,ab.
54. "short blessed test".ti,ab.
55. "short portable mental status questionnaire".ti,ab.
56. "spmsq".ti,ab.
57. "short test of mental status".ti,ab.
58. "telephone interview of cognitive status modified".ti,ab.
59. "tics-m".ti,ab.
60. "trail making test".ti,ab.
61. "verbal fluency categories".ti,ab.
62. "WORLD test".ti,ab.
63. "general practitioner assessment of cognition".ti,ab.
64. "GPCOG".ti,ab.
65. "Hopkins verbal learning test".ti,ab.
66. "HVLT".ti,ab.
67. "time and change test".ti,ab.
68. "modified world test".ti,ab.
69. "symptoms of dementia screener".ti,ab.
70. "dementia questionnaire".ti,ab.
71. "7MS".ti,ab.
72. ("concord informant dementia scale" or CIDS).ti,ab.
73. (SAPH or "dementia screening and perceived harm*").ti,ab.
74. or/1-73
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. ("lewy bod*" or DLB or LBD or FTD or FTLD or “frontotemporal lobar degeneration” or “frontaltemporal dement*).ti,ab.
81. "cognit* impair*".ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function* or degenerat* or deteriorat*)).ti,ab.
83. (memory adj3 (complain* or declin* or function* or disorder*)).ti,ab.
84. or/75-83
85. exp "sensitivity and specificity"/
86. "reproducibility of results"/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
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92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
95. specificit*.ab.
96. (ROC or "receiver operat*").ab.
97. Area under curve/
98. ("Area under curve" or AUC).ab.
99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab.
106. or/85-105
107. exp dementia/di
108. Cognition Disorders/di [Diagnosis]
109. Memory Disorders/di
110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. "neuropsychological test*".ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab.
118. (neuropsychological adj (assess* or evaluat* or test* or exam* or battery)).ti,ab.
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. exp Animals/ not Humans.sh.
131. 129 not 130
2 QUADAS-2
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Domain Patient selection Index test Reference standard Flow and timing
Description  
Describe methods of
patient selection: describe
included patients (prior
testing, presentation,
intended use of index test
and setting)
Describe the index
test and how it was
conducted and
interpreted
Describe the
reference standard
and how it was
conducted and
interpreted
Describe any patients who did not
receive the index test(s) and/or
reference standard or who were
excluded from the 2 x 2 table (refer
to flow diagram): describe the time
interval and any interventions
between index test(s) and
reference standard
Signalling
questions
(yes/no/unclear)
 
Was a consecutive or
random sample of patients
enrolled?
Was a case control design
avoided?
Did the study avoid
inappropriate exclusions?
 
Were the index test
results interpreted
without knowledge
of the results of the
reference
standard?
If a threshold was
used, was it pre-
specified?
 
Is the reference
standard likely to
correctly classify the
target condition?
Were the reference
standard results
interpreted without
knowledge of the
results of the index
test?
 
Was there an appropriate interval
between index test(s) and
reference standard?
Did all patients receive the same
reference standard?
Were all patients included in the
analysis?
Risk of bias:
(high/low/unclear)
Could the selection of
patients have introduced
bias?
Could the conduct
or interpretation of
the index test have
introduced bias?
Could the reference
standard, its
conduct, or its
interpretation have
introduced bias?
Could the patient flow have
introduced bias? 
Concerns
regarding
applicability:
(high/low/unclear)
Are there concerns that
the included patients do
not match the review
question?
Are there concerns
that the index test,
its conduct, or
interpretation differ
from the review
question?
Are there concerns
that the target
condition as defined
by the reference
standard does not
match the review
question?
—
Anchoring statements to assist with assessment of risk of bias
Domain 1: Patient selection
Risk of bias: could the selection of patients have introduced bias? (high, low, unclear)
Was a consecutive or random sample of patients enrolled?
Where sampling is used, the methods least likely to cause bias are consecutive sampling or random sampling, which should
be stated and/or described. Non-random sampling or sampling based on volunteers is more likely to be at high risk of bias.
Weighting: high risk of bias
Was a case-control design avoided?
Case control study designs have a high risk of bias, but sometimes they are the only studies available especially if the index
test is expensive and/or invasive. Nested case control designs (systematically selected from a defined population cohort) are
less prone to bias but they will still narrow the spectrum of patients that receive the index test. Study designs (both cohort
and case control) that may also increase bias are those designs where the study team deliberately increase or decrease the
proportion of subjects with the target condition, for example a population study may be enriched with extra dementia subjects
from a secondary care setting.
Weighting: high risk of bias
Did the study avoid inappropriate exclusions?
We will automatically grade the study as unclear if exclusions are not detailed (pending contact with study authors). Where
exclusions are detailed, we will grade the study as 'low risk' if exclusions are felt to be appropriate by the review
authors. Certain exclusions common to many studies of dementia are: medical instability; terminal disease; alcohol or
substance misuse; concomitant psychiatric diagnosis; other neurodegenerative condition. However if 'difficult to diagnose'
groups are excluded this may introduce bias, so exclusion criteria must be justified. For a community sample we would
expect relatively few exclusions. We will label post hoc exclusions 'high risk' of bias.
Weighting: high risk of bias
Applicability: are there concerns that the included patients do not match the review question? (high, low, unclear)
The included patients should match the intended population as described in the review question. If not already specified in
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the review inclusion criteria, setting will be particularly important – the review authors should consider population in terms of
symptoms; pre-testing; potential disease prevalence. We will classify studies that use very selected subjects or subgroups as
having low applicability, unless they are intended to represent a defined target population, for example, people with memory
problems referred to a specialist and investigated by lumbar puncture.
Domain 2: Index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias? (high/low/unclear)
Were the index test results interpreted without knowledge of the reference standard?
Terms such as 'blinded' or 'independently and without knowledge of' are sufficient and full details of the blinding procedure
are not required. This item may be scored as 'low risk' if explicitly described or if there is a clear temporal pattern to the order
of testing that precludes the need for formal blinding, that is all (neuropsychological test) assessments were performed
before the dementia assessment. As most neuropsychological tests are administered by a third party, knowledge of
dementia diagnosis may influence their ratings; tests that are self administered, for example using a computerized version,
may have less risk of bias.
Weighting: high risk of bias
Were the index test thresholds pre-specified?
For neuropsychological scales there is usually a threshold above which subjects are classified as 'test positive'; this may be
referred to as threshold, clinical cut-off or dichotomisation point. Different thresholds are used in different populations. A
study is classified as at higher risk of bias if the authors define the optimal cut-off post hoc based on their own study
data. Certain papers may use an alternative methodology for analysis that does not use thresholds and these papers should
be classified as not applicable.
Weighting: low risk of bias
Were sufficient data on (neuropsychological test) application given for the test to be repeated in an independent study?
Particular points of interest include method of administration (for example self completed questionnaire versus direct
questioning interview); nature of informant; language of assessment. If a novel form of the index test is used, for example a
translated questionnaire, details of the scale should be included and a reference given to an appropriate descriptive text, and
there should be evidence of validation.
Weighting: low risk of bias
Applicability: are there concerns that the index test, its conduct, or interpretation differ from the review question? (high, low,
unclear)
Variations in the length, structure, language, and/or administration of the index test may all affect applicability if they vary
from those specified in the review question. 
Domain 3: Reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias? (high, low, unclear)
Is the reference standard likely to correctly classify the target condition?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and
ICD-10. Criteria specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer's
dementia; McKeith criteria for Lewy Body dementia; Lund criteria for frontotemporal dementias; and the NINDS-AIREN
criteria for vascular dementia. Where the criteria used for assessment are not familiar to the review authors and the
Cochrane Dementia and Cognitive Improvement Group this item should be classified as 'high risk of bias'.
Weighting: high risk of bias
Were the reference standard results interpreted without knowledge of the results of the index test?
Terms such as 'blinded' or 'independent' are sufficient and full details of the blinding procedure are not required. This may be
scored as 'low risk' if explicitly described or if there is a clear temporal pattern to order of testing, i.e. all dementia
assessments performed before (neuropsychological test) testing.
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and
cognitive testing is a usual component of clinical assessment for dementia, however specific use of the scale under review in
the clinical dementia assessment should be scored as high risk of bias.
Weighting: high risk of bias
Was sufficient information on the method of dementia assessment given for the assessment to be repeated in an
independent study?
Particular points of interest for dementia assessment include the training and expertise of the assessor, whether additional
information was available to inform the diagnosis (for example neuroimaging, other neuropsychological test results), and
whether this was available for all participants.
Weighting: variable risk, but high risk if method of dementia assessment not described
Applicability: are there concerns that the target condition as defined by the reference standard does not match the review
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question? (high, low, unclear)
There is the possibility that some methods of dementia assessment, although valid, may diagnose a far smaller or larger
proportion of subjects with disease than in usual clinical practice. In this instance the item should be rated as having poor
applicability.
Domain 4: Patient flow and timing (Figure 1)
Risk of bias: could the patient flow have introduced bias? (high, low, unclear)
Was there an appropriate interval between the index test and reference standard?
For a cross-sectional study design, there is potential for the subject to change between assessments, however dementia is a
slowly progressive disease, which is not reversible. The ideal scenario would be a same-day assessment, but longer periods
of time (for example, several weeks or months) are unlikely to lead to a high risk of bias. For delayed-verification studies the
index and reference tests are necessarily separated in time given the nature of the condition.
Weighting: low risk of bias
Did all subjects receive the same reference standard?
There may be scenarios where subjects who score 'test positive' on the index test have a more detailed assessment for the
target condition. Where dementia assessment (or reference standard) differs between subjects this should be classified as
high risk of bias.
Weighting: high risk of bias
Were all subjects included in the final analysis?
Attrition will vary with study design. Delayed verification studies will have higher attrition than cross-sectional studies due to
mortality, and it is likely to be greater in subjects with the target condition. Dropouts (and missing data) should be accounted
for. Attrition that is higher than expected (compared to other similar studies) should be treated as a high risk of bias. We have
defined a cut-off of greater than 20% attrition as being high risk but this will be highly dependent on the length of follow-up in
individual studies.
Weighting: high risk of bias
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